Antibiotic levels measured in lungs of sickest pneumonia patients

NCT ID NCT04171674

Completed Knowledge-focused Sponsor: Centre Hospitalier Universitaire de Nīmes Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how the antibiotic ceftobiprole moves through the blood and lungs of 12 adults with severe pneumonia who were on breathing machines. Researchers gave a high dose continuously through a vein and took blood and lung fluid samples to measure drug levels. The goal was to find the best dose to fight the infection effectively.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ceftobiprole (a high-dose antibiotic given continuously through a vein)
What this could lead to: If successful, this could help doctors determine the right dose of ceftobiprole for critically ill pneumonia patients on ventilators.
What could go wrong: This is a very small, early-stage study (12 people) focused on drug levels, not on proving the drug works or is safe. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PNEUMONIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Community-Acquired Pneumonia pneumonia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PNEUMONIA

Contacts and locations

Locations

CHU de Nîmes

Nîmes, Gard, 30029, France
Centre Hospitalier Lyon Sud,

Pierre-Bénite, Auvergne-Rhône-Alpes, 69310, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.